Literature DB >> 30484408

One-year Outcome of Shanghai Mild Cognitive Impairment Cohort Study.

Bin Zhou1, Qianhua Zhao2,3,4, Shinsuke Kojima1, Ding Ding2,4, Satoshi Higashide1, Yoji Nagai1, Qihao Guo3,4, Tatsuo Kagimura1, Masanori Fukushima1, Zhen Hong2,3,4.   

Abstract

BACKGROUND &
OBJECTIVE: The purpose of this study is to identify the risk factors associated with the conversion from Mild Cognitive Impairment (MCI) to Alzheimer's Disease (AD) dementia for the early detection of AD.
METHODS: The study comprised a prospective cohort study that included 400 MCI subjects with annual follow-ups for 3 years.
RESULTS: During the first 12 months' follow-up, 42 subjects converted to Alzheimer's dementia (21 probable AD and 21 possible AD), two subjects converted to other types of dementia and 56 subjects lost follow. The factors associated with a greater risk of conversion from MCI to AD included gender, whole brain volume, and right hippocampal volume (rt. HV), as well as scores on the Revised Chinese version of the Alzheimer's Disease Assessment Scale-Cognitive subscale 13 (ADAS-Cog-C), Clock Drawing Test (CDT), Symbol Digit Modalities Test (SDMT), and Rey-Osterrieth Complex Figure Test (ROCFT). The risk classification of the combined ADAS-Cog-C and Alzheimer Cognitive Composite (ACC) score with the rt. HV and left Entorhinal Cortex Volume (lt. ECV) showed a conversion difference among the groups.
CONCLUSION: Early detection of AD and potential selection for clinical trial design should utilize the rt. HV, as well as neuropsychological test scores, including those of the ADAS-Cog-C and ACC. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Alzheimer cognitive composite score; Alzheimer's disease; Mild cognitive impairment; neuropsychological tests; risk factors; selective remindingzzm321990test.

Mesh:

Year:  2019        PMID: 30484408     DOI: 10.2174/1567205016666181128151144

Source DB:  PubMed          Journal:  Curr Alzheimer Res        ISSN: 1567-2050            Impact factor:   3.498


  6 in total

1.  The Influence of 24-h Ambulatory Blood Pressure on Cognitive Function and Neuropathological Biomarker in Patients With Alzheimer's Disease.

Authors:  Lixia Li; Weijia Wang; Tenghong Lian; Peng Guo; Mingyue He; Weijiao Zhang; Jinghui Li; Huiying Guan; Dongmei Luo; Weijia Zhang; Wei Zhang
Journal:  Front Aging Neurosci       Date:  2022-06-22       Impact factor: 5.702

2.  Plasma biomarker profiles and the correlation with cognitive function across the clinical spectrum of Alzheimer's disease.

Authors:  Zhenxu Xiao; Xue Wu; Wanqing Wu; Jingwei Yi; Xiaoniu Liang; Saineng Ding; Li Zheng; Jianfeng Luo; Hongchen Gu; Qianhua Zhao; Hong Xu; Ding Ding
Journal:  Alzheimers Res Ther       Date:  2021-07-05       Impact factor: 6.982

3.  Consistency and applicability of different brief screen instrument of cognitive function in elderly population.

Authors:  Lixia Lu; Lin Chen; Weiwen Wu; Yang Wang; Zhenbao Liu; Jun Xu; Qianhong Yang; Jun Zhao; Liangxian Liu; Hui Yu
Journal:  BMC Neurol       Date:  2021-03-01       Impact factor: 2.474

4.  Neuropsychological, neuropsychiatric, and quality-of-life assessments in Alzheimer's disease patients treated with plasma exchange with albumin replacement from the randomized AMBAR study.

Authors:  Mercè Boada; Oscar L López; Javier Olazarán; Laura Núñez; Michael Pfeffer; Orlando Puente; Gerard Piñol-Ripoll; José E Gámez; Fernando Anaya; Dobri Kiprov; Montserrat Alegret; Carlota Grifols; Miquel Barceló; Jordi Bozzo; Zbigniew M Szczepiorkowski; Antonio Páez
Journal:  Alzheimers Dement       Date:  2021-11-02       Impact factor: 16.655

5.  Economic evaluation of the screening for Alzheimer's disease in China.

Authors:  Yinan Ren; Dachuang Zhou; Qian Xing; Fangfang Gong; Wenxi Tang
Journal:  Front Aging Neurosci       Date:  2022-09-28       Impact factor: 5.702

6.  Protective Factors Modulate the Risk of Beta Amyloid in Alzheimer's Disease.

Authors:  Bin Zhou; Kenichiro Tanabe; Shinsuke Kojima; Satoshi Teramukai; Masanori Fukushima; The Alzheimer's Disease Neuroimaging Initiative
Journal:  Behav Neurol       Date:  2020-10-29       Impact factor: 3.342

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.